<DOC>
	<DOCNO>NCT02180828</DOCNO>
	<brief_summary>The study focus prove efficacy safety Clotrimazole vaginal tablet vs Fluconazole treatment severe vulvovaginal candidiasis</brief_summary>
	<brief_title>Clotrimazole Vaginal Tablet v Fluconazole Severe Vulvovaginal Candidiasis</brief_title>
	<detailed_description>The current study evaluate efficacy safety 2 dose 500 mg clotrimazole vaginal tablet administer intravaginally ( day 1 day 4 ) v.s 2 dose 150 mg fluconazole ( day 1 day 4 ) treatment severe vulvovaginal candidiasis.The number participant adverse event measure safety tolerability .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Clotrimazole</mesh_term>
	<criteria>1 . Vulvovaginal candidiasis infection diagnose , symptom evaluate use numerical rating system base severity ( absent=0 ; mild=1 ; moderate=2 ; severe=3 ) minimum VVC Composite Signs/Symptoms score 7 2 . Subject completes inform consent process 3 . Subject agrees take study medication schedule 4 . Subject complies clinical trial instruction . Commits followup visit 1. sexually transmitted disease gynaecological abnormality require treatment 2. disease know predispose candidiasis diabetes mellitus , receive antibiotic corticosteriods 3. pregnant 4. used antifungal medication week entry 5. expect menstruate within seven day start treatment 6. infect one candida specie</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>